What is ipamorelin?
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, identified from a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1. It releases growth hormone through a GHRP-like (ghrelin-type) receptor (Raun 1998). This page summarises the published studies and states where the evidence stops. Stackpure supplies ipamorelin for laboratory research only.
Potency and selectivity
In rat pituitary cells ipamorelin released growth hormone with an EC50 of 1.3 nmol/L (Emax 85%), and in conscious swine the ED50 was 2.3 nmol/kg. In swine it did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold above the ED50 for GH release, which the authors described as selectivity similar to GHRH (Raun 1998).
| Finding | Model | Source |
|---|---|---|
| EC50 1.3 nmol/L for GH release; ED50 2.3 nmol/kg in swine | Rat pituitary cells, conscious swine | Raun 1998 |
| No ACTH or cortisol release different from GHRH stimulation, even above 200-fold the GH ED50 | Swine | Raun 1998 |
| Terminal half-life 2 hours; clearance 0.078 L/h/kg; GH peaked at 0.67 hours | Healthy men, 15-minute infusions | Gobburu 1999 |
| No significant difference from placebo in time to first solid meal (25.3 vs 32.6 hours, p=0.15) | 117 patients after bowel resection, phase 2 | Beck 2014 |
Human studies
In healthy men given 15-minute infusions at five rates, ipamorelin showed dose-proportional kinetics with a terminal half-life of 2 hours, and GH was released in a single episode that peaked at 0.67 hours (Gobburu 1999). A phase 2 proof-of-concept trial of intravenous ipamorelin in 117 patients after bowel resection found no significant difference from placebo in time to tolerate a first solid meal, and the drug was well tolerated (Beck 2014). For comparisons see ipamorelin vs GHRP-6, ipamorelin vs sermorelin and ipamorelin vs CJC-1295.
What the sources do not show
- The selectivity data are from swine, and the human data are one pharmacokinetic study and one small trial in surgical patients.
- No source checked compares ipamorelin head to head with other secretagogues in humans.
- No source checked gives a research dose for Stackpure formats, and Stackpure does not give dosing guidance.
Related research products and tools
Frequently Asked Questions
What is ipamorelin?
A synthetic pentapeptide growth hormone secretagogue that acts through a GHRP-like receptor (Raun 1998).
Does ipamorelin raise cortisol?
In swine it did not release ACTH or cortisol at levels significantly different from GHRH stimulation (Raun 1998).
What is its half-life?
The terminal half-life was 2 hours in healthy men (Gobburu 1999).
Key References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PubMed 10496658
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PubMed 25331030
For research use only. Not for human consumption.